The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $18.38

Today's change0.00 0.00%
Updated May 28 4:00 PM EDT. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $18.38

Today's change0.00 0.00%
Updated May 28 4:00 PM EDT. Delayed by at least 15 minutes.

Meridian Bioscience Inc closed at (U.S.)$18.38.

Shares have lost 1.24% over the last five days, but have gained 11.66% over the last year to date. This security has underperformed the S&P 500 by 22.90% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $18.38
  • High--
  • Low--
  • Bid / Ask(U.S.) $17.96 / (U.S.) $19.95
  • YTD % change+11.66%
  • Volume0
  • Average volume (10-day)339,252
  • Average volume (1-month)292,372
  • Average volume (3-month)275,510
  • 52-week range(U.S.) $15.56 to (U.S.) $21.30
  • Beta1.42
  • Trailing P/E22.07×
  • P/E 1 year forward21.41×
  • Forward PEG1.34×
  • Indicated annual dividend(U.S.) $0.80
  • Dividend yield4.35%
  • Trailing EPS(U.S.) $0.83
Updated May 28 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.09%

Based on its net profit margin of 18.09%, Meridian Bioscience Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue52484747
Total other revenue--------
Total revenue52484747
Gross profit33292829
Total cost of revenue19191818
Total operating expense36353534
Selling / general / administrative13131313
Research & development3333
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----0--
Other operating expenses, total--------
Operating income16131213
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax16121213
Income after tax10889
Income tax, total5444
Net income10889
Total adjustments to net income--------
Net income before extra. items10889
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items10889
Inc. avail. to common incl. extra. items10889
Diluted net income10889
Dilution adjustment------0
Diluted weighted average shares42424242
Diluted EPS excluding extraordinary itemsvalue per share0.240.190.200.21
Dividends per sharevalue per share0.200.200.200.20
Diluted normalized EPSvalue per share0.240.190.200.21